Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Respiratory (Asthma/COPD) (May 2017)

Posted by Matt Breese on May 5, 2017

Find me on:

According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A look at market access over the past two quarters shows that the percentage of restricted lives in both the medicare and health exchange channels increased. Similarly, the amount of multiple product step edits increased.


Source: MMIT data as of Q2 2017

Trends:  Recent news related to asthma/COPD treatments show the willingness of prescribers to work with pharmaceutical manufacturers and payer to develop a more streamlined drug pricing model. Related to this, value-based care implicates disease areas like respiratory significantly, which is starting to shift prescribing habits in this space.

To read the full Reality Check on respiratory with key findings on clinical characteristics, asthma/COPD drug market access and payer coverage, please click on the button below: 


View Reality Check


Topics: Specialty, Market Access, Branding & Marketing